Progenics Pharmaceuticals (NASDAQ:PGNX) Receiving Somewhat Favorable News Coverage, Accern Reports

Press coverage about Progenics Pharmaceuticals (NASDAQ:PGNX) has been trending somewhat positive on Tuesday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Progenics Pharmaceuticals earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.8617117149849 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Progenics Pharmaceuticals stock traded up $0.07 during trading hours on Tuesday, hitting $7.33. 758,785 shares of the company were exchanged, compared to its average volume of 1,351,057. Progenics Pharmaceuticals has a 1 year low of $4.60 and a 1 year high of $8.63. The company has a debt-to-equity ratio of 0.74, a current ratio of 6.31 and a quick ratio of 6.31. The stock has a market capitalization of $531.89, a PE ratio of -8.14 and a beta of 2.45.

How to Become a New Pot Stock Millionaire

Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.21) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.21). The business had revenue of $3.90 million during the quarter, compared to analysts’ expectations of $3.18 million. Progenics Pharmaceuticals had a negative return on equity of 87.30% and a negative net margin of 436.08%. The company’s quarterly revenue was down 15.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.10) earnings per share. equities research analysts anticipate that Progenics Pharmaceuticals will post -0.8 EPS for the current year.



A number of brokerages have weighed in on PGNX. BidaskClub upgraded Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 14th. Cantor Fitzgerald set a $15.00 price target on Progenics Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, March 8th. Zacks Investment Research cut Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 14th. Finally, ValuEngine cut Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 16th. Two research analysts have rated the stock with a sell rating, three have given a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $12.35.

COPYRIGHT VIOLATION WARNING: This story was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://stocknewstimes.com/2018/04/18/progenics-pharmaceuticals-pgnx-receiving-somewhat-positive-news-coverage-study-finds.html.

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Insider Buying and Selling by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply